{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.97","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.85","value":"1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.00","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.50","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.45","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.91","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.87","value":"7.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.69","value":"7.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.64","value":"12.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Cycle 10 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.62","value":"11.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Cycle 11 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.06","value":"16.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.54","value":"6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 13 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.43","value":"12.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Cycle 14 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.36","value":"6.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.70","value":"5.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.62","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 17 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.53","value":"11.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.26","value":"11.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 19 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be calculated as n = 1.","groupId":"OG000","spread":"NA","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.19","value":"16.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 21 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.19","value":"16.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 22 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be calculated as n = 1.","groupId":"OG000","spread":"NA","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 23 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be calculated as n = 1.","groupId":"OG000","spread":"NA","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be calculated as n = 1.","groupId":"OG000","spread":"NA","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 25 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be calculated as n = 1.","groupId":"OG000","spread":"NA","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 26 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.85","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"}],"units":"Participants"}],"title":"End of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"}],"units":"Participants"}],"description":"EQ-5D-5L is designed as an international, standardized, instrument for describing and evaluating quality of life (QoL). In the EQ-5D-5L VAS participants are asked to indicate their health state today on a VAS with the endpoints labeled 'the best health you can imagine' (score 100) and 'the worst health you can imagine' (score 0).\n\nA higher score on the VAS indicates better health related QoL. A positive change from baseline indicates an improvement in health related QoL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.","id":"OG000","title":"Loncastuximab Tesirine"}],"paramType":"MEAN","populationDescription":"Patient reported outcome (PRO) population. Only participants with data available for analysis are included. Overall number of participants analyzed prepresents all participants who contributed data to this assessment, though not all participants contributed data to each time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 2 to 26 (cycle duration of 3 weeks), and end of treatment (up to 599 days)","title":"Change From Baseline Score in the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS)","type":"SECONDARY","unitOfMeasure":"score on a scale"}